Hydrogen-rich water in patients with interstitial cystitis and painful bladder syndromeScientific Research
Effect of Supplementation With Hydrogen-rich Water in Patients With Interstitial Cystitis/Painful Bladder Syndrome
Abstract
Objective
To study the efficacy of hydrogen-rich water in the treatment of patients with interstitial cystitis/painful bladder syndrome (IC/PBS).
Methods
We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial of hydrogen-rich water in patients with IC/PBS. Inclusion criteria were stable IC/PBS symptoms for ≥12 weeks after hydrocystitis, an Interstitial Cystitis Symptom Index score ≥7, and bladder pain (Interstitial Cystitis Symptom Index Question 4) ≥4. They were randomized 2:1 to receive hydrogen-rich water or placebo water for 8 weeks. Symptoms were assessed using the Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index, Patient Symptom Scale for Pelvic Pain and Parsons Urgency/Frequency, Bladder Pain Score on the Visual Analogue Scale, and a standard 3-day voiding diary. The primary outcome was improvement in patient-reported symptoms as assessed after treatment.
Results
A total of 30 participants (29 women and 1 man, age 64.0 ± 14.8 years) participated in the study, and 2 patients (both women) withdrew from the study. Bladder pain scores were significantly lower in both groups. However, the effect of hydrogen-rich water on symptoms was not significantly different from placebo, although supplementation with hydrogen-rich water was extremely effective in improving bladder pain scores in 11% of patients.
Conclusion
The results of this study do not support the use of hydrogen-rich water supplementation for the treatment of IC/PBS patients.
References
- Impaired bladder perfusion in interstitial cystitis: a study of blood supply using laser Doppler flowmetry.
J Urol. 1993; 149: 890-892
- Comparison of bladder blood flow in patients with and without interstitial cystitis.
J Urol. 1999; 162: 330-334
- Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors.
J Urol. 2004; 172: 945-948
- Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial.
J Urol. 2006; 176: 1442-1446
- Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan.
BMC Urol. 2011; 11: 11
- Reperfusion injury of the rat bladder is worse than ischemia.
J Urol. 2003; 170: 2086-2090
- The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis.
J Urol. 2003; 169: 1564-1568
- Effect of eviprostat on bladder overactivity in an experimental cystitis rat model.
Int J Urol. 2008; 15: 356-360
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals.
Nat Med. 2007; 13: 688-694
- Japanese guideline for diagnosis and treatment of interstitial cystitis.
Int J Urol. 2009; 16: 4-16
- Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome.
Int J Urol. 2009; 16: 597-615
- The Interstitial Cystitis Symptom Index and Problem Index.
Urology. 1997; 49: 58-61
- Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity.
Urology. 2002; 60: 573-578
- Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance.
Nutr Res. 2008; 28: 137-143
- Hydrogen-rich pure water prevents superoxide formation in brain slices of vitamin C-depleted SMP30/GNL knockout mice.
Biochem Biophys Res Commun. 2008; 375: 346-350
- Causative significance of bladder blood flow in lower urinary tract symptoms.
Int J Urol. 2012; 19: 20-25
- Hyperbaric oxygen therapy for radiation-induced haemorrhagic cystitis.
BJU Int. 2005; 96: 107-109
- What is oxidative stress?.
Metabolism. 2000; 49: 3-8
- Vascular endothelial cells synthesise nitric oxide from l-arginine.
Nature. 1988; 333: 664-666
- Urinary nitric oxide synthase activity and cyclic GMP levels are decreased with interstitial cystitis and increased with urinary tract infections.
J Urol. 1996; 155: 1432-1435
- A randomized double-blind placebo-controlled crossover trial of the efficacy of l-arginine in the treatment of interstitial cystitis.
BJU Int. 2000; 85: 421-426
- The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer.
Pharmacol Rev. 2000; 52: 673-751
- Quercetin suppresses proinflammatory cytokines production through MAP kinases and NF-kappaB pathway in lipopolysaccharide-stimulated macrophage.
Mol Cell Biochem. 2003; 243: 153-160
- Treatment of interstitial cystitis with a quercetin supplement.
Tech Urol. 2001; 7: 44-46
- A pilot open label study of CystoProtek in interstitial cystitis.
Int J Immunopathol Pharmacol. 2005; 18: 183-188
- Electrolyzed-reduced water scavenges active oxygen species and protects DNA from oxidative damage.
Biochem Biophys Res Commun. 1997; 234: 269-274
- Anti-diabetic effects of electrolyzed reduced water in streptozotocin-induced and genetic diabetic mice.
Life Sci. 2006; 79: 2288-2292
DOI: 10.1016
Published on: 20230102
Effect of Supplementation With Hydrogen-rich Water in Patients With Interstitial Cystitis/Painful Bladder Syndrome
Abstract
Objective
To study the efficacy of hydrogen-rich water in the treatment of patients with interstitial cystitis/painful bladder syndrome (IC/PBS).
Methods
We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial of hydrogen-rich water in patients with IC/PBS. Inclusion criteria were stable IC/PBS symptoms for ≥12 weeks after hydrocystitis, an Interstitial Cystitis Symptom Index score ≥7, and bladder pain (Interstitial Cystitis Symptom Index Question 4) ≥4. They were randomized 2:1 to receive hydrogen-rich water or placebo water for 8 weeks. Symptoms were assessed using the Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index, Patient Symptom Scale for Pelvic Pain and Parsons Urgency/Frequency, Bladder Pain Score on the Visual Analogue Scale, and a standard 3-day voiding diary. The primary outcome was improvement in patient-reported symptoms as assessed after treatment.
Results
A total of 30 participants (29 women and 1 man, age 64.0 ± 14.8 years) participated in the study, and 2 patients (both women) withdrew from the study. Bladder pain scores were significantly lower in both groups. However, the effect of hydrogen-rich water on symptoms was not significantly different from placebo, although supplementation with hydrogen-rich water was extremely effective in improving bladder pain scores in 11% of patients.
Conclusion
The results of this study do not support the use of hydrogen-rich water supplementation for the treatment of IC/PBS patients.
References
J Urol. 1993; 149: 890-892
J Urol. 1999; 162: 330-334
J Urol. 2004; 172: 945-948
J Urol. 2006; 176: 1442-1446
BMC Urol. 2011; 11: 11
J Urol. 2003; 170: 2086-2090
J Urol. 2003; 169: 1564-1568
Int J Urol. 2008; 15: 356-360
Nat Med. 2007; 13: 688-694
Int J Urol. 2009; 16: 4-16
Int J Urol. 2009; 16: 597-615
Urology. 1997; 49: 58-61
Urology. 2002; 60: 573-578
Nutr Res. 2008; 28: 137-143
Biochem Biophys Res Commun. 2008; 375: 346-350
Int J Urol. 2012; 19: 20-25
BJU Int. 2005; 96: 107-109
Metabolism. 2000; 49: 3-8
Nature. 1988; 333: 664-666
J Urol. 1996; 155: 1432-1435
BJU Int. 2000; 85: 421-426
Pharmacol Rev. 2000; 52: 673-751
Mol Cell Biochem. 2003; 243: 153-160
Tech Urol. 2001; 7: 44-46
Int J Immunopathol Pharmacol. 2005; 18: 183-188
Biochem Biophys Res Commun. 1997; 234: 269-274
Life Sci. 2006; 79: 2288-2292
